Ovarian cancer combo shows promise in maintenance therapy

NCT ID NCT06121401

Ongoing Disease control Sponsor: Mario Negri Institute for Pharmacological Research Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase IV trial tests whether the drugs olaparib and bevacizumab, taken together after initial chemotherapy, can help prevent ovarian cancer from coming back in women with a specific genetic marker (HRD-positive). About 190 participants who have already responded to first-line treatment will receive the combination as maintenance therapy. The study aims to confirm how well this approach works in everyday medical practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: olaparib (Lynparza) and bevacizumab
What this could lead to: If successful, this could confirm that combining olaparib with bevacizumab helps keep advanced ovarian cancer from coming back longer after initial treatment.
What could go wrong: This is a phase IV trial confirming real-world use, not a new breakthrough. Results may show limited benefit or side effects like fatigue, nausea, or high blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, OVARIAN EPITHELIAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Carcinoma, Ovarian Epithelial fallopian tube cancer fallopian tube serous adenocarcinoma ovarian carcinoma ovarian epithelial tumor primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, OVARIAN EPITHELIAL

Contacts and locations

Locations

A.O. Ordine Mauriziano

Torino, Italy
A.O.U. Citta della Salute e della Scienza

Torino, Italy
AOU Parma

Parma, Italy
Arcispedale Santa Maria Nuova

Reggio Emilia, Italy
Azienda Socio Sanitaria Territoriale (ASST) Lariana

San Fermo della Battaglia, Como, 22042, Italy
Istituto Europeo di Oncologia

Milan, Italy
Istituto Nazionale dei Tumori

Milan, Italy
Istituto Oncologico Veneto IRCCS

Padova, 35128, Italy
Ospedale Manzoni

Lecco, Italy
Ospedale San Luca

Lucca, Italy
Ospedale Santa Chiara

Pisa, Italy
Ospedale Umberto I

Roma, Italy
Policlinico Careggi

Florence, Italy
Spedali Civili

Brescia, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.